Hope for Vasculitis: How Adalimumab Offers a New Path to Remission
"Exploring the potential of Adalimumab in treating Hepatitis B virus-negative polyarteritis nodosa, offering renewed hope for patients struggling with disease relapse and treatment failure."
Polyarteritis nodosa (PAN) presents a significant challenge in rheumatology due to its rarity and complexity. This primary systemic vasculitis (PSV) primarily affects medium- or small-sized arteries, distinguishing itself by its lack of association with anti-neutrophil cytoplasmic antibodies (ANCA). Historically, PAN's natural progression led to severe outcomes; however, the introduction of corticosteroids marked a turning point, significantly improving survival rates.
Current therapeutic strategies for PAN are stratified by the Five-Factor Score (FFS), a prognostic tool developed by the French Vasculitis Study Group. Patients without FFS typically undergo treatment with corticosteroids alone, whereas those with critical organ involvement—including renal, gastrointestinal, and cardiac manifestations—receive a combination of corticosteroids and cyclophosphamide. In cases where these standard treatments fail or the disease relapses, biologic agents are considered.
This article examines the potential of adalimumab (ADA), a TNF monoclonal antibody (mAb), in managing PAN, particularly in patients experiencing relapse. By sharing the findings of a case study, we shed light on how ADA can induce clinical remission and prevent disease flares, offering a promising outlook for individuals grappling with this challenging condition.
Adalimumab’s Documented Uses and Outcomes
DailyMed lists HUMIRA (adalimumab) as a TNF blocker indicated for reducing signs and symptoms, inducing major clinical response, inhibiting structural damage progression, and improving physical function in adults with moderately to severely active rheumatoid arthritis. In a report on refractory cutaneous polyarteritis nodosa, no adverse events or recurrence were noted during 18 months of adalimumab treatment. These sources illustrate both an established indication for adalimumab and a reported vasculitis case with sustained disease control.
Broad Immunosuppression and Careful Guidance
The Johns Hopkins Vasculitis Center explains that vasculitis treatments suppress parts of the immune system and that early strategies used broadly acting immunosuppressive drugs. The American College of Rheumatology and Vasculitis Foundation guidelines are intended to help medical practitioners guide treatment, while their plain-language versions emphasize information most patients need to know. UpToDate notes that treatment recommendations for specific forms of vasculitis are reviewed separately, underscoring that management depends on the particular disorder rather than a single universal regimen.
Adalimumab: A Ray of Hope for Relapsing Vasculitis?
In August 2012, a 42-year-old Han Chinese male sought medical attention at the dermatology clinic of National Cheng Kung University Hospital, presenting with a six-month history of purpuric reticulate erythema and nodules on his lower extremities. A nodule biopsy revealed dense infiltrates composed of abundant neutrophils and lymphocytes surrounding a subcutaneous small artery, accompanied by neutrophilic fibrin-platelet thrombus in the lumen, consistent with the histopathological characteristics of PAN.
- Initial Treatment: The patient was initially diagnosed with PAN based on the 2012 updated Chapel Hill consensus definitions and treated with high-dose corticosteroids (1 mg/kg/day prednisolone).
- Maintenance Therapy: Upon achieving clinical remission, the prednisolone dosage was gradually reduced and replaced with azathioprine (2 mg/kg/day).
- Relapse: Despite maintenance therapy, the patient experienced a relapse, characterized by recurrent weight loss, right ankle swelling, right testicular pain, and new-onset hypertension.
- Adalimumab Intervention: Due to the patient's preference against corticosteroids and their side effects, adalimumab (ADA) 40mg biweekly subcutaneous injection was prescribed without other immunosuppressive agents from October 2014 to December 2016.
- Outcomes: The ADA treatment resulted in the absence of ankle swelling and testicular pain, with no disease flares or infection complications during the 26-month treatment period.
Promising Evidence with Important Safety Signals
A 2026 review of polyarteritis nodosa and related vasculitides reports that there are no high-quality randomized controlled trials of treatment in idiopathic PAN. At the same time, case reports describe serious events associated with adalimumab: one 2024 patient developed vasculitis linked to adalimumab after infections and malignancies were excluded, and her ischemic lesions resolved after discontinuation, high-dose glucocorticoids, and intravenous pulse cyclophosphamide. Another report identifies leukocytoclastic vasculitis as the most common form of cutaneous vasculitis that may be associated with TNF inhibitors and notes prior reports linking adalimumab with lupus and vasculitis.
Evidence Remains Limited and Mixed
A systematic review of polyarteritis nodosa treatments found a paucity of high-quality randomized controlled trials, limiting confidence in comparative treatment conclusions. In contrast, a report on hepatitis B virus-negative polyarteritis nodosa states that observations in one patient suggest a potential effect of adalimumab in controlling disease activity. Another case describes worsening nonperfusion and vasculitis despite cyclosporine, followed by initiation of biweekly adalimumab monotherapy after both prior agents were discontinued; the patient was monitored for five years, including an attempted medication taper.
Comparisons Across Therapies and Biosimilars
A 2022 Bayesian network meta-analysis examined which targeted rheumatoid arthritis therapy was more likely to achieve an ACR50 response with good safety at 24 weeks, while noting that few head-to-head randomized clinical trials had compared adalimumab with other targeted therapies. A comparative study also evaluated adalimumab versus tocilizumab in patients with Takayasu arteritis. Separately, the Vizient comparison reports that all 10 adalimumab biosimilars had approval for conditions including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, inflammatory bowel disease, plaque psoriasis, hidradenitis suppurativa, and uveitis.
A Promising Step Forward
This case study illuminates the potential of adalimumab as an effective treatment for PAN, especially in cases of relapse. While further research through large-scale randomized trials is necessary, these findings offer a beacon of hope for individuals grappling with this difficult-to-treat condition.
Rare but Serious Patient Experiences
A case-based review describes leukocytoclastic vasculitis induced by an adalimumab biosimilar in an elderly woman with rheumatoid arthritis. Another report links adalimumab to moderate-sized vascular vasculitis after other potential causes, including infections and malignancies, were excluded; stopping adalimumab and giving high-dose glucocorticoids and intravenous pulse cyclophosphamide resolved her ischemic lesions. A separate clinical discussion warns that adalimumab, used for moderate to severe Crohn’s disease, can rarely be associated with painful and pruritic papules of leukocytoclastic vasculitis and recommends punch biopsy when LCV is suspected.